Mizuho Analysts Give AveXis (NASDAQ:AVXS) a $147.00 Price Target

AveXis (NASDAQ:AVXS) received a $147.00 target price from equities researchers at Mizuho in a research report issued to clients and investors on Wednesday, March 14th. The firm currently has a “buy” rating on the stock. Mizuho’s price objective points to a potential upside of 26.82% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. BMO Capital Markets reaffirmed a “buy” rating on shares of AveXis in a research report on Monday, January 8th. Chardan Capital reaffirmed a “buy” rating and issued a $135.00 price objective on shares of AveXis in a research report on Friday, January 5th. Morgan Stanley set a $120.00 price target on AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. UBS set a $122.00 price target on AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Citigroup set a $132.00 price target on AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $123.90.

How to Become a New Pot Stock Millionaire

Shares of AveXis stock opened at $115.91 on Wednesday. AveXis has a 52 week low of $65.23 and a 52 week high of $138.46.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($2.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). research analysts predict that AveXis will post -7.63 EPS for the current year.

In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $126.19, for a total transaction of $224,618.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $118.07, for a total value of $1,771,050.00. Following the sale, the insider now owns 1,792,147 shares of the company’s stock, valued at $211,598,796.29. The disclosure for this sale can be found here. Insiders have sold a total of 68,780 shares of company stock valued at $8,341,178 over the last 90 days. 18.60% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP purchased a new stake in AveXis in the third quarter valued at about $39,563,000. Advisory Research Inc. raised its stake in AveXis by 25.5% in the fourth quarter. Advisory Research Inc. now owns 16,821 shares of the company’s stock valued at $1,862,000 after buying an additional 3,423 shares during the last quarter. Candriam Luxembourg S.C.A. raised its stake in AveXis by 14.0% in the third quarter. Candriam Luxembourg S.C.A. now owns 28,500 shares of the company’s stock valued at $2,757,000 after buying an additional 3,500 shares during the last quarter. State of Wisconsin Investment Board raised its stake in AveXis by 55.0% in the fourth quarter. State of Wisconsin Investment Board now owns 24,800 shares of the company’s stock valued at $2,745,000 after buying an additional 8,800 shares during the last quarter. Finally, Emory University raised its stake in AveXis by 3.4% in the fourth quarter. Emory University now owns 18,474 shares of the company’s stock valued at $2,045,000 after buying an additional 607 shares during the last quarter. Institutional investors own 82.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mizuho Analysts Give AveXis (NASDAQ:AVXS) a $147.00 Price Target” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/avexis-avxs-pt-set-at-147-00-by-mizuho.html.

About AveXis

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply